Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →"Vintafolide is a promising and innovative late-stage cancer drug candidate...This agreement underscores our strategy of building a portfolio of oncology…
"The acceptance of the EMA filing for vintafolide is an important milestone for Merck and Endocyte," said Gary Gilliland, oncology franchise head, Merck…
Coverage of PROCEED halt noted the trial failure came just over a month after EMA's positive conditional approval opinion, making the reversal especially…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Merck-Endocyte exclusive worldwide agreement on vintafolide. $120M upfront, up to $880M in dev/reg/commercial milestones across 6 cancer indications. 50/50 US profit share, double-digit ex-US royalty. Phase 3 PROCEED trial in platinum-resistant ovarian cancer.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Endocyte, Inc. (this deal) | 2012 | $1.0B | — |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2022 | $250M | 86 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
← Browse all deals · How we score deals
More: 2012 deals · Merck & Co. Inc. deals · Oncology deals